Literature DB >> 26360673

Regression of Acanthosis Nigricans with the Addition of Sitagliptin and Pioglitazone.

E M Adderley-Rolle1, S Peter2.   

Abstract

Acanthosis nigricans (AN) is a cutaneous disorder associated with various diseases. There are few documented cases of regression of AN. We discuss a case of a 48-year old diabetic woman with resolution of AN after treatment with sitagliptin and pioglitazone.

Entities:  

Year:  2014        PMID： 26360673      PMCID： PMC4696637          DOI： 10.7727/wimj.2013.334

Source DB:  PubMed          Journal:  West Indian Med J        ISSN： 0043-3144            Impact factor:   0.171


  3 in total

Review 1.  Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans.

Authors:  P D Cruz; J A Hud
Journal:  J Invest Dermatol       Date:  1992-06       Impact factor: 8.551

2.  The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

Authors:  C R Kahn; J S Flier; R S Bar; J A Archer; P Gorden; M M Martin; J Roth
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

3.  Regression of acanthosis nigricans correlates with disappearance of anti-insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome.

Authors:  Gilbert G Fareau; Mario Maldonado; Elif Oral; Ashok Balasubramanyam
Journal:  Metabolism       Date:  2007-05       Impact factor: 8.694
  3 in total
  2 in total

Review 1.  Current treatment options for acanthosis nigricans.

Authors:  Nupur U Patel; Catherine Roach; Hossein Alinia; William W Huang; Steven R Feldman
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-08-07

2.  Effectiveness and Safety of Metformin versus Canthex™ in Patients with Acanthosis Nigricans: A Randomized, Double-blind Controlled Trial.

Authors:  Arindam Sett; Samiksha Pradhan; Karan Sancheti; Dibyendu Basu; Adrija Datta; Lekha Biswas; Sayan Das; Subhasis Kumar Pal; Nidhi Gupta; Amrita Sil; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2019 Mar-Apr       Impact factor: 1.494
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.